IF revealed strong OLFML3 expression in the tumor vasculature of colorectal and uterus cancers (Figure 1A,B, Figure S1A,F), intermediate expression was observed in lung and prostate carcinomas (Figure S1A,D,E), and low to undetectable expression was observed in the vessels of the kidney and esophageal cancers relative to healthy control tissues (Figure S1A–C). Here, OLFML3 is linked to prostate carcinoma.